But new data from a recent clinical trial suggests that a previously discontinued experimental drug, called gantenerumab, ...

A new study conducted by researchers from the Washington University School of Medicine identified an experimental drug that ...

For some people with a high risk of Alzheimer's who received a drug called gantenerumab for eight years, their risk of ...

The study evaluated Roche’s gantenerumab in 73 participants aged between 30 to 50 with rare, inherited genetic mutations that ...

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from ...

Hazard ratio for clinical decline in Clinical Dementia Rating-Sum of Boxes was 0.53 for those treated with gantenerumab the longest ...

Washington University School of Medicine led a study evaluating long-term gantenerumab treatment in individuals with ...

A clinical trial involving individuals genetically predisposed to develop early-onset Alzheimer’s disease suggests that ...

The first evidence that removing amyloid plaques may delay Alzheimer’s symptoms has now been published. In The Lancet Neurology on March 19, scientists led by Randall Bateman at Washington University ...

A study of Roche's anti-amyloid drug gantenerumab has suggested that early treatment to remove amyloid plaques from the brain ...

Alzheimer’s disease is usually associated with old age. But around 5%-10% of all Alzheimer’s cases occur in people under the age of 65. Early-onset Alzheimer’s disease progresses more rapidly and ...

Long-term removal of amyloid beta in people genetically destined to develop Alzheimer's disease may have delayed symptoms and ...